Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Congenital combined deficiency of coagulation factors VII and X--different genetic mechanisms.

Haemophilia : the official journal of the World Federation of Hemophilia·2015

Same author

[Diagnosis of inherited diseases of platelet function. Interdisciplinary S2K guideline of the Permanent Paediatric Committee of the Society of Thrombosis and Haemostasis Research (GTH e. V.)].

Hamostaseologie·2014

Same author

Common genetic variants of homocysteine metabolism in ischemic stroke: a case-control study.

European journal of neurology·2005

Same author

Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin.

Neurology·2005

Same author

Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke.

Neurology·2004

Same author

Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin.

Neurology·2004

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Old and new anticoagulants.

¹Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Germany. ursula.harbrecht@ukb.uni-bonn.de

Hamostaseologie

|February 12, 2011

Summary

New oral anticoagulants offer promising alternatives to traditional vitamin-K antagonists (VKAs) for thrombosis treatment. While effective and safer in studies, long-term adherence and use in specific patient groups require further investigation before replacing VKAs.

Area of Science:

Pharmacology
Hematology
Thrombosis Management

Background:

Vitamin-K antagonists (VKAs) and heparins have been mainstays in thrombosis treatment for decades.
VKAs, unlike heparins, lack pharmacological modification but benefit from improved monitoring (INR, self-management).
Understanding VKA's interaction with VKORC1 aids in comprehending coumarin sensitivity and resistance.

Purpose of the Study:

To review the development and profile of new oral anticoagulants.
To compare their efficacy, safety, and administration with existing anticoagulants like VKAs and heparins.
To identify potential limitations and areas for future research regarding novel anticoagulants.

Main Methods:

Review of clinical studies on new oral anticoagulants.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: Jun 4, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Comparison of direct thrombin inhibitors (e.g., dabigatran) and factor Xa inhibitors (e.g., rivaroxaban) with VKAs and heparins.

Analysis of efficacy, safety, pharmacokinetics, and administration of novel agents.

Main Results:

New oral anticoagulants directly target specific clotting factors (IIa or Xa) with shorter half-lives than VKAs.
Studies indicate non-inferior or superior efficacy compared to enoxaparin and VKAs, with comparable safety.
Fixed dosing and broader therapeutic width are advantages, eliminating the need for anticoagulation bridging.

Conclusions:

New oral anticoagulants are highly promising for thrombosis prevention and treatment.
Potential limitations include gastrointestinal side effects, specific metabolism/elimination routes, and lack of specific antidotes.
Further research is needed on adherence, safety in risk patients, dosage adjustments, and drug interactions before VKA replacement.